COVID-19 doesn’t just impact the body directly but can also awaken dormant viruses like Epstein-Barr and Anelloviridae, according to a large study involving hospitals across the U.S. This viral reactivation is now tied to the development of long COVID and lasting health challenges.
- COVID-19 can reactivate latent viruses, including Epstein-Barr and herpes.
- Anelloviridae virus reactivation is linked to long COVID and lasting disability.
- Inflammation—not immunosuppression—may trigger viral reactivation during illness.
What happened
Researchers at Boston Children's Hospital and partners conducted the largest biomarker study of COVID-19 to date, following over 1,100 hospitalized patients across 20 U.S. institutions. Using genomic sequencing, they identified reactivation of 11 dormant viruses within 40 days of hospitalization, including Epstein-Barr, cytomegalovirus, herpes simplex, and Anelloviridae virus.
The study, funded by the National Institutes of Health, found that viral reactivation often occurred alongside systemic inflammation in patients. This challenges the typical assumption that viruses reactivate mainly due to immune system suppression. Instead, inflammation triggered by severe COVID-19 can wake these hidden viruses.
Why it feels good
Discovering the link between the reactivation of dormant viruses and long COVID sheds light on why some individuals face lingering symptoms and disability months after initial recovery. The identification of Anelloviridae’s role, a virus present latent in most people, provides a promising lead in understanding the complex biology behind persistent post-COVID illness.
This insight opens new avenues for diagnostics and treatments, signaling hope for the millions worldwide enduring long COVID. By better understanding these viral triggers, medical strategies can evolve to improve recovery outcomes and provide relief from chronic symptoms that have remained puzzling so far.
What to enjoy or watch next
Future research will focus on how the immune system responds to these reactivated viruses over the course of COVID-19 illness and recovery. Scientists aim to determine optimal timing and methods for treatments that can target these secondary viral activations to reduce long-term impacts.
Monitoring developments from this area can help us prepare for future coronavirus outbreaks by learning how to manage viral reactivations effectively. Staying informed about ongoing studies may offer new hope for improving care for patients affected by long COVID and related viral complications.